0.02
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioxytran
From its filings with the US Securities and Exchange Commission
Bioxytran is based in Needham, Massachusetts and is incorporated in Nevada. Its shares trade on OTC under the ticker BIXT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2017, it reported revenue of $191,077.
02494. There are four wholly owned subsidiaries specialized in specific aspects of the business.
Blood Brain Barrier (the “BBB”) and has low viscosity allowing it to safely deliver oxygen to the brain.
These treatments may also be used for the treatment of other types of viral infections, such as influenza.
(SAE’s) in the patient population or viral rebounds by day fourteen (14) in the patient population.
These treatments may also be used for the treatment of other types of viral infections, such as influenza.
(SAE’s) in the patient population or viral rebounds by day fourteen (14) in the patient population.
Quoted from its 10-K, filed 15 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Jan 2010
- Employees
- 2
- Website
- us-rem.com ↗
- Head office
- C/O BIOXYTRAN, INC., NEEDHAM, MA, 02494
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. David PlattChairman of the Board, President, Chief Executive Officer, since 2018$223,506
- Mr. Ola SoderquistChief Financial Officer, Treasurer, Secretary$433,506
- Mr. Mike SheikhChief Communications Officer$280,000
- Dr. Dale ConawayIndependent Director$471,568
- Dr. Alan HobermanIndependent Director$471,568
- Dr. Radka MilanovaIndependent Director$82,645
- Mr. Anders UtterIndependent Director$471,568
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bioxytran Inc possesses a unique and innovative technology that has the potential to revolutionize the field of oxygen therapeutics. This technology sets the company apart from its competitors and offers a significant advantage in the market.
- The company has a dedicated and highly skilled team of researchers and scientists who continuously work on advancing the technology and developing new applications. This commitment to research and development ensures that Bioxytran Inc stays at the forefront of innovation.
Weaknesses
- Despite its unique technology, Bioxytran Inc currently has limited market presence. The company needs to invest more resources in marketing and sales efforts to increase awareness and expand its customer base.
- The continuous focus on research and development requires significant investments, which can strain the company's financial resources. Finding a balance between innovation and cost management is essential for Bioxytran Inc's long-term success.
Opportunities
- The market for oxygen therapeutics is expected to grow due to the rising prevalence of chronic diseases and the aging population. This presents Bioxytran Inc with an opportunity to capitalize on this increasing demand and expand its customer base.
- Bioxytran Inc can explore potential partnerships with pharmaceutical companies or medical device manufacturers to leverage their expertise, resources, and distribution networks. Collaborations can accelerate market penetration and enhance product development capabilities.
Threats
- The oxygen therapeutics market is highly competitive, with several established players and new entrants. Bioxytran Inc needs to differentiate itself and demonstrate the superiority of its technology to overcome competition and gain market share.
- Developing and commercializing medical products involves navigating through complex regulatory processes and obtaining necessary approvals. Regulatory hurdles pose a risk to Bioxytran Inc's timeline and market entry strategies, requiring dedicated efforts and expertise in compliance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.